NeuroNOS, a Beyond Air subsidiary, secured $2 million in private equity funding to advance the preclinical development of a novel small-molecule drug for autism spectrum disorder (ASD). The drug, deliverable via injection or orally, aims to regulate nitric oxide (NO) levels in the brain, addressing a key biological mechanism implicated in ASD. NeuroNOS continues to pursue additional funding to support further development and upcoming clinical trials.
This development holds significant promise for the ASD community, which currently lacks FDA-approved treatments directly targeting the core biological mechanisms of the condition. The drug’s potential to address the root cause of ASD, rather than just managing symptoms, offers a new avenue for improving the lives of individuals with autism. The research behind this drug, validated in various models, suggests it could address synaptic dysfunction, potentially improving both behavioral and cognitive function. This targeted approach could lead to more effective therapies and a better understanding of ASD itself.
The initial $2 million investment fuels the drug’s preclinical development. NeuroNOS has partnered with a U.S.-based contract manufacturer to ensure high-quality drug production and scalable manufacturing. Current formulation development focuses on subcutaneous injection for optimal bioavailability, with plans for an oral formulation to enhance accessibility for children. First-in-human studies are anticipated in 2026.
This funding and the focused development plan signal a significant step towards a potential breakthrough in ASD treatment. If successful, the NeuroNOS drug could not only fill a major unmet need for patients but also pave the way for similar NO-modulating therapies for other complex neurological conditions. This innovative approach represents a crucial advancement in the pursuit of effective treatments for ASD and underscores the potential for targeted therapies to significantly impact the lives of those affected.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
